1. RPS Diagnostics develops novel point-of-care technology platforms, reagents, and therapeutic agents for eye care and infectious disease testing. 2. Their proprietary platforms include InflammaDry for dry eye detection and FebriDx for respiratory fever testing. They have 3 additional POC tests in clinical trials and a robust pipeline of products. 3. Their products help physicians provide better patient management by reducing misdiagnosis, unnecessary treatment, and disease spread through rapid, easy-to-use testing. This improves patient outcomes and lowers costs.

1. 1
RPS Diagnostics
Proprietary and Confidential to RPS

2. 2
RPS Diagnostics
Reagents and ELISA
Molecular platform
Therapeutics
Immunodiagnostics
Novel point-of-care (POC)
technology platforms, therapeutic
agents, and proprietary reagents

3. 3
Value Proposition
Eye Care
Professionals
(Ophthalmology and Optometry)
Primary/Urgent Care
and Government
(Retail health, U.S. stockpile,
and
foreign governments)
Nucleic Acid
Development
Platform Technology
Proven, Proprietary
Platform Technology
Globally Available
POC Tests
AdenoPlus®
Adenoviral conjunctivitis
InflammaDry®
Dry eye
CE-marked POC Test
FebriDx™
Viral/bacterial
immune response
3 additional POC tests
in clinical trials and/or
development
Robust Pipeline
Market Potential
(U.S., Europe, Japan)
≥ $1 billion
≥ $2.5 billion
≥ $2.5 billion

4. 4
Pathogen Directed Therapy
Immune Response Directed Therapy
Diagnostic Directed Therapy
AdenoPlus
Adenoviral
conjunctivitis
InflammaDry
Dry eye
FebriDx
Respiratory fever

5. 5
Bridging the Gap
RPS products bridge the gap between current clinical practice and the
standard of care, helping physicians provide the best possible patient
management while acting as good stewards of therapeutic resources.
*FebriDx is CE marked and is available for sale in Europe. FebriDx has not received FDA clearance and is not commercially available in the United States.

6. 6
Benefits to
physician and
patient
Reduce
misdiagnosis
Reduce
spread
of disease
Reduce
empiric
treatment
Improved patient outcomes
Reduced costs
Rapid, Easy to Use Testing Platform

7. 7
Dry Eye Disease and MMP-9
Matrix metalloproteinases (MMP) are proteolytic enzymes that
are produced by stressed epithelial cells on the ocular surface1-2
 Elevated MMP-9:
 Correlates with clinical exam findings
 Causes epithelial cell disruption that leads to corneal staining
 Precedes corneal staining
 Leads to pain and fluctuating vision
[1] Chotikavanich S, de Paiva CS, Li de Q, et al. Production and activity of matrix metalloproteinase-9 on the ocular surface increase in dysfunctional tear syndrome. Invest
Ophthalmol Vis Sci. 2009 Jul;50(7):3203-9. [2] Sambursky R, Davitt WF 3rd, Friedberg M, Tauber S. Prospective, multicenter, clinical evaluation of point-of-care matrix
metalloproteinase-9 test for confirming dry eye disease. Cornea. 2014 Aug;33(8):812-8.

8. 8
Importance of Identifying MMP-9
InflammaDry detects elevated levels of MMP-9, facilitating
better management of…
 Patients who present with signs or symptoms of dry eye
 Patients preparing for ocular surgery such as LASIK or cataract surgery
 Prevent surgical complications and prevent worsening dry eye
 Keratoconus (ectasia) associated with elevated MMP-9 and improves with
cyclosporine therapy
 Contact lens patients to better prevent and manage lens intolerance
 Daily disposable lenses and faster fittings
 Glaucoma patients to identify patients with significant underlying
ocular surface inflammation to guide therapeutic options
 Early SLT and preservative free medications
[1] Trattler W, Goldberg D, Reilly C. Incidence of concomitant cataract and dry eye: prospective health assessment of cataract patients. Presented at: World Cornea Congress;
April 8,2010;Boston,MA. [2] Ambrosio R. J Refract Surg 2008; 24:396-407. [3] Fournie PR, Gordon GM, Dawson DG, et al. Arch Ophthalmol 2010; 128:426-436.

9. 9
InflammaDry Helps Guide Therapeutic Decisions
Elevated MMP-9 may predict which patients
will respond to anti-inflammatory therapy.5
[1] Schiffman RM, Walt JG, Jacobsen G, et al. Utility assessment among patients with dry eye disease. Ophthalmology 2003;110:1412-1419. [2] Shtein RM. Post-LASIK dry eye.
Expert Rev Ophthalmol. 2011 Oct;6(5):575-582. [3] Sambursky R, O’Brien TP. MMP-9 and the perioperative management of LASIK surgery. Curr Opin Ophthalmol. 2011
Jul;22(4):294-303. [4] Marsh P, Pflugfelder SC. Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjögren syndrome. Ophthalmology. 1999
Apr;106(4):811-6. [5] Kaufman HE. The practical detection of MMP-9 diagnoses ocular surface disease and may help prevent its complications. Cornea. 2013 Feb;32(2):211-6.

10. 10
RPS obtained strategic access to two unique, complementary
therapeutic assets
Seeking a partner, or partners, to support development and
commercialization
Therapeutics
 Histatin – topical wound healing
therapeutic for eyes and skin that
stimulates epithelial and fibroblast
migration and enhances re-
epithelialization
 Anti-presbyopia therapeutic – a novel
topical drop that transiently reduces
the need for reading glasses

11. 11
Thank you!